Fanconi Anemia Mesenchymal Stromal Cells‐Derived Glycerophospholipids Skew Hematopoietic Stem Cell Differentiation Through Toll‐Like Receptor Signaling. (24th July 2015)

• Record Type: Journal Article
• Authors: Amarachintha, Surya; Sertorio, Mathieu; Wilson, Andrew; Li, Xiaoli; Pang, Qishen
• Is Part Of: Stem cells. Volume 33:Number 11(2015:Nov.)
• Page Start: 3382
• Page End: 3396
• Publication Date: 2015-07-24
• Subjects: Fanconi anemia -- Marrow stromal stem cells -- Hematopoietic stem cell transplantation -- Myeloid cells; Cloning -- Periodicals; Clone cells -- Periodicals; Stem cells -- Periodicals; Cell Differentiation -- Periodicals; Cell Division -- Periodicals; Clone Cells -- Periodicals; Hematopoietic Stem Cells -- Periodicals; Stem Cells -- Periodicals; 571.84
• DOI: 10.1002/stem.2100
• Languages: English
• ISSNs: 1066-5099

Abstract

Abstract: Fanconi anemia (FA) patients develop bone marrow (BM) failure or leukemia. One standard care for these devastating complications is hematopoietic stem cell transplantation. We identified a group of mesenchymal stromal cells (MSCs)‐derived metabolites, glycerophospholipids, and their endogenous inhibitor, 5‐(tetradecyloxy)−2‐furoic acid (TOFA), as regulators of donor hematopoietic stem and progenitor cells. We provided two pieces of evidence that TOFA could improve hematopoiesis‐supporting function of FA MSCs: (a) limiting‐dilution cobblestone area‐forming cell assay revealed that TOFA significantly increased cobblestone colonies in Fanca−/− or Fancd2−/− cocultures compared to untreated cocultures. (b) Competitive repopulating assay using output cells collected from cocultures showed that TOFA greatly alleviated the abnormal expansion of the donor myeloid (CD45.2+Gr1+Mac1+) compartment in both peripheral blood and BM of recipient mice transplanted with cells from Fanca−/− or Fancd2−/− cocultures. Furthermore, mechanistic studies identified Tlr4 signaling as the responsible pathway mediating the effect of glycerophospholipids. Thus, targeting glycerophospholipid biosynthesis in FA MSCs could be a therapeutic strategy to improve hematopoiesis and stem cell transplantation. Stem Cells 2015;33:3382–3396